135 related articles for article (PubMed ID: 21542017)
1. Mortalin inhibition in experimental Parkinson's disease.
Chiasserini D; Tozzi A; de Iure A; Tantucci M; Susta F; Orvietani PL; Koya K; Binaglia L; Calabresi P
Mov Disord; 2011 Aug; 26(9):1639-47. PubMed ID: 21542017
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Calabresi P; Mercuri NB; Sancesario G; Bernardi G
Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
[TBL] [Abstract][Full Text] [Related]
3. A2A adenosine receptor antagonists protect the striatum against rotenone-induced neurotoxicity.
Belcastro V; Tozzi A; Tantucci M; Costa C; Di Filippo M; Autuori A; Picconi B; Siliquini S; Luchetti E; Borsini F; Calabresi P
Exp Neurol; 2009 May; 217(1):231-4. PubMed ID: 19416678
[TBL] [Abstract][Full Text] [Related]
4. Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.
Tantucci M; Mariucci G; Taha E; Spaccatini C; Tozzi A; Luchetti E; Calabresi P; Ambrosini MV
Neuroscience; 2009 Oct; 163(3):735-40. PubMed ID: 19580850
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition.
Costa C; Belcastro V; Tozzi A; Di Filippo M; Tantucci M; Siliquini S; Autuori A; Picconi B; Spillantini MG; Fedele E; Pittaluga A; Raiteri M; Calabresi P
J Neurosci; 2008 Aug; 28(32):8040-52. PubMed ID: 18685029
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiological actions of zonisamide on striatal neurons: Selective neuroprotection against complex I mitochondrial dysfunction.
Costa C; Tozzi A; Luchetti E; Siliquini S; Belcastro V; Tantucci M; Picconi B; Ientile R; Calabresi P; Pisani F
Exp Neurol; 2010 Jan; 221(1):217-24. PubMed ID: 19913015
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
8. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
9. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
10. Mortalin is Expressed by Astrocytes and Decreased in the Midbrain of Parkinson's Disease Patients.
Cook TJ; Hoekstra JG; Eaton DL; Zhang J
Brain Pathol; 2016 Jan; 26(1):75-81. PubMed ID: 26095919
[TBL] [Abstract][Full Text] [Related]
11. Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Domenici MR; Potenza RL; Martire A; Coccurello R; Pèzzola A; Reggio R; Tebano MT; Popoli P
J Neurosci Res; 2005 Jun; 80(5):646-54. PubMed ID: 15880742
[TBL] [Abstract][Full Text] [Related]
12. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
[TBL] [Abstract][Full Text] [Related]
13. Regenerative effects of peptide nanofibers in an experimental model of Parkinson's disease.
Sever M; Turkyilmaz M; Sevinc C; Cakir A; Ocalan B; Cansev M; Guler MO; Tekinay AB
Acta Biomater; 2016 Dec; 46():79-90. PubMed ID: 27619838
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
15. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
16. The subthalamic activity and striatal monoamine are modulated by subthalamic stimulation.
Yamamoto T; Uchiyama T; Sakakibara R; Taniguchi J; Kuwabara S
Neuroscience; 2014 Feb; 259():43-52. PubMed ID: 24291727
[TBL] [Abstract][Full Text] [Related]
17. Mortalin sensitizes human cancer cells to MKT-077-induced senescence.
Deocaris CC; Widodo N; Shrestha BG; Kaur K; Ohtaka M; Yamasaki K; Kaul SC; Wadhwa R
Cancer Lett; 2007 Jul; 252(2):259-69. PubMed ID: 17306926
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
19. Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease.
McCabe K; Concannon RM; McKernan DP; Dowd E
J Neuroimmunol; 2017 Sep; 310():103-106. PubMed ID: 28778432
[TBL] [Abstract][Full Text] [Related]
20. Altered neuronal activity in the pedunculopontine nucleus: An electrophysiological study in a rat model of Parkinson's disease.
Geng X; Xie J; Wang X; Wang X; Zhang X; Hou Y; Lei C; Li M; Qu Q; He T; Han H; Yao X; Wang M
Behav Brain Res; 2016 May; 305():57-64. PubMed ID: 26924016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
